Harrow (HROW) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026Financial performance and balance sheet
Five-year revenue CAGR exceeded 40% and adjusted EBITDA CAGR exceeded 60%; FY26 revenue guidance is $350m–$365m.
Q3 2026 record revenue exceeded $99m, including $83.5m of branded revenue at ~80% gross margin; period-end cash was ~$75m.
Q4 adjusted EBITDA guidance is >$33m, versus $21.2m recently reported.
$300m of unsecured notes carry an 8.625% coupon and are due in ~4 years.
Core brand performance
VEVYE Q3 revenue was ~$40m, up 75% YoY; prescriptions rose 83% YoY and revenue grew 35% sequentially; 10.7m additional commercial lives are expected from Jan. 1, 2027.
IHEEZO Q3 revenue exceeded $25m, up 15%, with unit demand up 21%; a 25% net price increase took effect July 1, 2026, and Q4 is expected to be its strongest quarter yet.
IHEEZO lost cataract-surgery pass-through status at end-Q1 2026, removing that market; Q3 unit demand still grew 21% YoY after an initial demand decline of >20%.
TRIESENCE Q3 revenue exceeded $10m, up 186%, with unit demand up 110%; coverage exceeds 95% and patient out-of-pocket cost is ~$38.
TRIESENCE phase IV cataract-surgery data are expected in H1 2027; a next-generation version is targeted for NDA filing in 2027 and launch in 2028 or early 2029.
Operating leverage and commercial platform
SG&A as a share of revenue declined from 84% in H1 2026 to 54% in Q3; Q2-to-Q3 SG&A was flat as revenue increased ~$28m, with $22m reaching the profit line.
Revenue is expected to outgrow costs, with operating leverage potentially increasing over coming quarters.
Four commercial teams cover ocular surface, retina, surgery, and compounded medications; planned launches through 2030 are intended to use existing teams and add one product each year.
Latest events from Harrow
- Record branded-led Q3 growth; FY revenue held, but Adjusted EBITDA outlook reset above $40M.HROW
Q3 2026 - Long-term strategy targets $250M quarterly revenue by 2027, driven by G-MELT, IHEEZO, and VEVYE.HROW
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 revenue grew 11% YoY to $70.7M, with guidance reaffirmed and TYRVAYA acquisition announced.HROW
Q2 2026 - Accelerating growth driven by innovative eye care products and strong 2026 financial outlook.HROW
46th Annual William Blair Growth Stock Conference - Q1 2026 revenue was $44.2M, with strong product growth and improved liquidity.HROW
Q1 2026 - Key votes on directors, executive pay, and auditor set for June 2026 annual meeting.HROW
Proxy filing - Proxy covers director elections, say-on-pay, auditor ratification, and strong governance practices.HROW
Proxy filing - Double-digit growth and expanding ophthalmic launches drive strong future outlook.HROW
Leerink Global Healthcare Conference 2026 - Targets $250M+ quarterly revenue by Q4 2027, led by new launches and expanded access.HROW
Investor Day 2025